Business Context and Reporting Period
ADC Therapeutics SA (ADCT) filed an 8-K on December 3, 2025, reporting updated data from the LOTIS-7 Phase 1b clinical trial. The trial evaluates the combination of ZYNLONTA and glofitamab (COLUMVI) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The data cutoff date was November 17, 2025.
Key Financial Metrics
This filing is a Current Report (Item 8.01) focused on clinical trial results and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Highlights
The report details significant efficacy and safety data for 49 efficacy-evaluable patients with at least 6 months of follow-up:
- Overall Response Rate (ORR): 89.8% (44/49 patients). At the selected 150 μg/kg dose, ORR was 85.7%.
- Complete Response (CR) Rate: 77.6% (38/49 patients). At the selected 150 μg/kg dose, CR was 75.0%.
- Population Breakdown:
- Relapsed patients (n=24): 100% ORR, 91.7% CR.
- Primary refractory patients (n=25): 80% ORR, 64% CR.
- CAR-T pretreated patients (n=8): 6 achieved CR.
- Response Conversion: 14 patients converted from stable disease or partial response to complete response over time.
Outlook, Risks, and Safety Profile
The combination was described as generally well tolerated with a manageable safety profile. Key safety observations include:
- Grade 3+ Adverse Events: Neutropenia (32.7%), GGT increased (16.3%), anemia (10.2%), and WBC decreased (8.2%).
- Grade 5 Adverse Events: Occurred in 2 patients (4.1%), one at each dose level. One was deemed treatment-related.
- Cytokine Release Syndrome (CRS): 36.7% across all grades. At the selected 150 μg/kg dose, CRS was 25.0%, with all but one case being low grade.
- Neurotoxicity (ICANS): 4.1% across dose levels, limited to Grade 1/2.
The filing does not provide specific forward-looking financial guidance or updated commercial outlook beyond the clinical data.
Investor Verification Checklist
- Verify the durability of the 77.6% complete response rate in the full patient population.
- Confirm the long-term safety profile regarding the two Grade 5 adverse events reported.
- Monitor the progression of the 14 patients who converted to complete response over time.
- Assess the impact of these results on the regulatory pathway for the ZYNLONTA and glofitamab combination.